Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Ascent of Abbott: Humira Marketer Battles With FDA Over Biosimilars

This article was originally published in RPM Report

Executive Summary

Abbott Labs wasn’t considered a serious biologics manufacturer when the biosimilars pathway was first being debated. But with the arthritis treatment Humira now the world’s best-selling pharmaceutical brand, the company has assumed a leadership position just as the biosimilar opportunity is emerging. And what better way to use that new role than by launching an offensive strike against FDA?

You may also be interested in...



Defender Or Opponent? Amgen Straddles The Biosimilar Line

Amgen revealed plans to develop and launch biosimilar versions of Abbott’s Humira and Johnson & Johnson’s Remicade – two competitors to its blockbuster anti-TNF Enbrel – during an investor meeting in New York City Feb. 7.

Biosimilarity vs. “Cognitive Dissonance”: The Ongoing Challenges to New FDA Pathway

FDA is still awaiting its first biosimilar product application – and there is no reason to expect a flood of products any time soon. The new pathway faces legal, logistical and resource obstacles. But the most important barrier may be the need for a mindset change.

Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy

The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS081014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel